Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL992646 | 1.00 | CETP (1.00) | CETP | |
| SCHEMBL6591108 | 0.92 | CETP (0.85) | CETP | |
| SCHEMBL6591118 | 0.92 | CETP (0.85) | CETP | |
| Torcetrapib SCHEMBL126708 | 0.91 | CETP (1.00) | CETP | |
| Torcetrapib SCHEMBL49081 | 0.91 | CETP (1.00) | CETP | |
| Torcetrapib SCHEMBL6277910 | 0.91 | CETP (1.00) | CETP | |
| Torcetrapib SCHEMBL7169875 | 0.91 | CETP (1.00) | CETP | |
| Torcetrapib SCHEMBL10041443 | 0.91 | CETP (1.00) | CETP | |
| Torcetrapib SCHEMBL29403162 | 0.91 | CETP (1.00) | CETP | |
| SCHEMBL13454994 | 0.91 | CETP (0.82) | CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040039018-A1 | CETP inhibitors in combination with antihypertensive agents and uses thereof | PFIZER INC. | 2004-02-26 | — | — | US | claimed |
| WO-2005117869-A1 | COMBINATIONS COMPRISING (S)-AMLODIPINE AND A CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITOR, AND METHODS FOR REDUCING HYPERTENSION | SEPRACOR INC. (US) | 2005-12-15 | — | — | WO | disclosed |
| EP-1114032-B1 | 4-AMINO SUBSTITUTED-2-SUBSTITUTED-1,2,3,4-TETRAHYDROQUINOLINES AS CETP INHIBITORS | PFIZER PROD INC (US) | 2004-06-02 | — | — | EP | disclosed |
| US-20040039018-A1 | CETP inhibitors in combination with antihypertensive agents and uses thereof | PFIZER INC. | 2004-02-26 | — | — | US | disclosed |
| US-6489478-B1 | CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH INHIBITORS AND THE USE OF SUCH INHIBITORS TO ELEVATE CERTAIN PLASMA LIPID LEVELS, INCLUDING HIGH DENSITY LIPOPROTEIN-CHOLESTEROL AND TO LOWER CERTAIN | PFIZER INC. | 2002-12-03 | — | — | US | disclosed |
| US-6140343-A | CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS WHICH ARE USED TO ELEVATE HIGHDENSITY LIPOPROTEIN-CHOLESTEROL AND TO LOWER LOW DENSITY LIPOPROTEIN-CHOLESTEROL AND TRIGLYCERIDES; FOR TREATING ATHEROSCLEROSIS, PERIPHERAL VASCULAR DISEASE, OBESITY | PFIZER (US) | 2000-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039018-A1 | CETP inhibitors in combination with antihypertensive agents and uses thereof | CETP, MTTP, APOB | CETP 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.